Compare ESRT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESRT | PHAT |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.4M | 894.0M |
| IPO Year | 2012 | 2019 |
| Metric | ESRT | PHAT |
|---|---|---|
| Price | $5.74 | $12.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.35 | ★ $19.83 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $768,270,000.00 | $175,110,000.00 |
| Revenue This Year | $4.26 | $93.04 |
| Revenue Next Year | $1.52 | $58.91 |
| P/E Ratio | $22.66 | ★ N/A |
| Revenue Growth | 0.05 | ★ 216.93 |
| 52 Week Low | $4.87 | $3.69 |
| 52 Week High | $8.76 | $18.31 |
| Indicator | ESRT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 60.42 | 50.49 |
| Support Level | $4.87 | $10.38 |
| Resistance Level | $7.04 | $12.44 |
| Average True Range (ATR) | 0.18 | 1.03 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 90.91 | 64.24 |
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.